Every treatment Ive had has been nothing short of amazing
The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
ACS Omega 10 (23), 2401824029
The tirzepatide dosing conversion chart helps map between delivery methods
Retatrutide was originally developed by Eli Lilly and is being studied for its triple-action mechanism across GLP-1, GIP and glucagon receptors
Sellers operating exclusively through Instagram, TikTok, Facebook Marketplace, Telegram, or similar platforms are almost never legitimate pharmacies
